Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

• Status: Recruiting
• Trial end date: 2024-12-30
• Target enrollment: 0
• Participant gender: All

Summary

patients with locally advanced cancer of oropharynx, hypopharynx or larynx and CPS>1 will recieve 3 cycles of induction immunochemotherapy with platinum, 5-FU and pembrolizumab followed by (chemo)radiation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: City Clinical Oncology Hospital No 1
• Collaborators: Moscow City Oncology Hospital No. 62; Moscow Clinical Scientific Center
• Treatments: Cisplatin; Pembrolizumab

Criteria

Inclusion Criteria:

• Squamous cell cancer of oropharynx (p16+: T0-3N3, T4N0-3, p16- : T3-4aN0-1, T1-4aN2-3), hypopharynx (T2-3N0-3, T1N+, T4aN0-3) or larynx III-IVa (T1-2N2-3, T3N2-3, T4aN0-3) , TNM8 staging classification;

• Tumor is morphlogically confirmed;

• CPS>1 (22C3 clone);

• ECOG 0-2;

• Age above 18 years;

• Signed Informed consent form.

Exclusion Criteria:

• Cancer of nasopharynx;

• Non-squamous cell carcimomas or absense of morphological confirmation of squamous cell cancer;

• Stages I or II;

• ECOG>=3.